title: Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network For Organ Sharing Database.
abstract: BACKGROUND
  The availability of suitable lung and heart-lung allografts for transplantation remains poor. Accepting organs from donors with positive serological studies for hepatitis B could potentially expand the donor pool. The aim of this study was to assess the impact of donor hepatitis B core antibody (HBcAb) status on outcomes of lung and heart-lung transplant recipients.
  
  
  METHODS
  Using United Network for Organ Sharing/Organ Procurement and Transplantation Network data, we compared outcomes of 13,233 recipients of HBcAb negative organs with 333 recipients of HBcAb positive donor organs.
  
  
  RESULTS
  We found that the unadjusted 1-year survival of recipients of HBcAb positive donor was worse, but there was no difference in survival after adjusting for baseline donor and recipient differences. On multivariate analysis, recipient and donor age, procedure type, era of transplant, baseline medical condition, diagnosis, and donor hepatitis C antibody status impacted 1- and 5-year survival. However, donor HBcAb status did not impact 1- or 5-year survival posttransplant.
  
  
  CONCLUSIONS
  Lung and heart-lung allografts from HBcAb positive donors may be safely used, which would increase the number of transplants performed without compromising recipient outcomes.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA 94505, USA. gdhillon@stanford.edu
authors.forename: Gundeep S
authors.initials: GS
authors.lastname: Dhillon
authors.forename: Joseph
authors.initials: J
authors.lastname: Levitt
authors.forename: Hari
authors.initials: H
authors.lastname: Mallidi
authors.forename: Vincent G
authors.initials: VG
authors.lastname: Valentine
authors.forename: Meera R
authors.initials: MR
authors.lastname: Gupta
authors.forename: Ramachandra
authors.initials: R
authors.lastname: Sista
authors.forename: David
authors.initials: D
authors.lastname: Weill
mesh_terms: D000328:Adult; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D016041:Heart-Lung Transplantation / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data; D006509:Hepatitis B / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000097:blood*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016040:Lung Transplantation / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data; D008297:Male; D012307:Risk Factors; D014019:Tissue Donors / Q000706:statistics & numerical data*; D009927:Tissue and Organ Procurement / Q000706:statistics & numerical data
chemical_list: D006510:Hepatitis B Antibodies